FOCUS Analyst chez Nemera. devices that accompany the patient through all the stages of administration. “Studies 2- Sécuriser l’administration de nouvelles show that the number of patients taking molécules biologiques à forte valeur their treatment correctly can increase by ajoutée. Le nombre de pompes électroniques 20% to 60% if offering them an electronic portables (wearables) va ainsi exploser dans reminder”, Hadrien Gremillet, Senior le monde passant de 526 millions en 2016 à Strategic Market Analyst at Nemera, plus de 1,1 milliard en 2022. points out. 3- Garantir l’observance au traitement. C’est l’axe privilégié par les plates-formes 2-Securing the administration of new eNovelia et eAdvancia qui apportent un biological molecules with high added feedback jusque sur la conformité du geste value. The number of wearable electronic effectué (coordination bien faite) et l’état dupumps will explode worldwide passing dispositif (pompe désamorcée…). from 526 million in 2016 to more than 1.1 billion in 2022. Hadrien Gremillet, Senior Strategic 4- L’adoption de l’électronique par les Market Analyst chez Nemera. patients au quotidien (montres, balances 3- Guaranteeing treatment adherence. Hadrien Gremillet, Senior Strategic connectées…) avec le développement de This is the main focus of the eNovelia Market Analyst at Nemera. l’IoT. « Les patients sont prêts à avoir une and eAdvancia platforms, which provide santé connectée permettant un suivi plus feedback up to gesture compliance (correct 4 CHANGE DRIVERS POUR exhaustif etpartage avec leur médecin », coordination) and the status of the device L’ADOPTION DES E-DEVICES rappelle Hadrien Grémillet. On estime que (unprimed pump, etc.). 50 % des patients utilisent une application SELON NEMERA mobile de suivi de santé et de bien-être (allant du calcul du nombre de pas jusqu’à la 4- The adoption of electronics by patients 1- Avec le développement de l’ambulatoire, on a daily basis (watches, connected encourager l’administration à domicile vérification de leur diabète). scales, ...) along with the development avec des dispositifs intelligents faciles of IoT. “Patients are ready to have their à utiliser accompagnant le patient dans 4 CHANGE DRIVERS health connected in order to benefit toutes les étapes de l’administration. FOR THE ADOPTION OF from a more exhaustive follow-up and « Des études montrent que le nombre E-DEVICES ACCORDING are willing to share with their doctor”, de patients prenant correctement leur TO NEMERA he reminds. It is estimated that 50% of traitement peut augmenter de 20 % patients use a mobile health and well- à 60 % en leur proposant un rappel 1- Along with the development of being monitoring application (from électronique » explique Hadrien outpatient care, encouraging home calculating the number of steps to Gremillet, Senior Strategic Market administration with easy-to-use smart checking their diabetes). “The related publications will enable us to Other companies are also working on this pressurized metered dose inhalers (pMDI) bettercharacterize the impact of Mallya® type of projects, starting from the giant is to ensure patient compliance and pro- on the efficacy of treatments and enter Medtronic to the French start-up Diabe- per use of the device, as the vast majority the reimbursement system in France and loop and Roche Diabetes Care, in the sense of patients are unable to achieve correct in Europe”, announced Arnaud Guillet of personalization through Artificial Intelli- «hand-to-mouth coordination» (system for Biocorp, which is preparing to invest gence (AI). activation and inspiration). “Our Inspair in the next six months in new premises smart sensor allows us to monitor whether in Clermont Ferrand (Puy-de-Dôme) to Dose and usage control the treatment has been taken correctly increase their capabilities in the manual and for inhalation and whether the patient’s gesture is well semi-manual assembly of electronic compo- integrated in the long term,” points out nents. As for the other areas in the diabetes In the inhalation segment, the main appli- Arnaud Guillet. Biocorp has entered an sector, Abbott is working with BigFoot on cations deal with asthma and chronic agreement with Lindal to develop a custo- the development of an artificial pancreas, a obstructive pulmonary diseases (COPD), mized version of Inspair for its conventio- pump that would deliver insulin automati- which are still misdiagnosed, under-treated nal pMDI. A mobile app allows patients cally based on blood glucose measurements. or not treated at all. A challenge related to to access their feedback and then share it January - 2020 / The Pharmaceutical Post 01 47 KCAP